There are a large number of people using opioid medication as painkillers. As per the statistics by the United Nations Office on Drugs and Crime, almost 26.4 to 36 million people abused opioid globally in 2012. Due to an increase in the rate of addiction and severe side-effects associated with the prolonged use of opioid medication there has been an increased demand for the use of non-opioid therapeutics. The mode of action of non-opioid medications are analgesic, antipyretic, and anti-inflammatory. These medications decrease the development of pain mediators in the peripheral nervous system by preventing the enzyme cyclooxygenase at the site of injury, which in turn blocks the production of prostaglandins.

The rise in the incidence of pain disorders has increased the demand for different approaches for pain management. In addition, an increase in costs-associated with the treatment and growing number of people with chronic and acute pain are some of the major driving factors for the market growth. Moreover, the growing awareness regarding the side-effects related with frequent opioid use has further boosted the demand for non-opioid medication. A rise in the abuse of opioid medication has also increased the R&D to develop non-opioid medication, which will further fuel the market growth. However, side-effects with prolonged and excessive use of non-opioid medication such as damage to the liver or kidneys can hamper the market growth.

The global non-opioid pain patch market is segmented based on patch type, distribution, and geography. Based on patch type, the market is segmented into capsaicin patches, lidocaine patches, diclofenac patches, ketoprofen patches, methyl salicylate patches, and others. Based on distribution channels, the market is categorized into hospital pharmacies, online pharmacies, independent pharmacies, and drug stores. Based on geography, the market has been examined across North America, Europe, Asia-Pacific, and LAMEA.

Comprehensive competitive analysis and profiles of major market players such as Teikoku Seiyaku Co., Ltd., Mylan N.V., GlaxoSmithKline plc, Teh Seng Pharmaceutical Mfg. Co., Ltd., Allergan, Pfizer, Inc., Hisamitsu Pharmaceutical Co. Inc., Acorda Therapeutics, and IBSA Institut Biochimque SA, Inc. have also been provided in this report.

Key Benefits

• This report provides an extensive analysis of the current and emerging market trends and dynamics in the global market.
• This report entails a detailed quantitative analysis of the current market and estimations from 2017-2023, which assists in identifying prevailing market opportunities.
• The projections in this report are made by analyzing the current trends and future market potential from 2017 to 2023 in terms of value.
• Competitive intelligence (of leading manufacturers and distributors of non-opioid pain patches) helps understand the competitive scenario globally.
• An in-depth analysis of current research and clinical developments within the market has been provided with key market dynamic factors that help understand the behavior of the market.

Non-opioid Pain Patch Market Key Segments:

By Patch Type

• Capsaicin Patches
• Lidocaine Patches
• Diclofenac Patches
• Ketoprofen Patches
• Methyl Salicylate Patches
• Others

By Distribution Channel

• Hospital Pharmacies
• Online Pharmacies
• Independent Pharmacies & Drug Stores

By Region

• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • Germany
  • France
  • UK
  • Italy
  • Spain
  • Rest of Europe
• Asia-Pacific
  • Japan
  • China
  • Australia
  • India
  • South Korea
  • Taiwan
  • Rest of Asia-Pacific
• LAMEA
  • Brazil
  • Turkey
  • Saudi Arabia
  • South Africa
  • Rest of LAMEA

CHAPTER 1 INTRODUCTION

1.1. REPORT DESCRIPTION
1.2. KEY BENEFITS
1.3. KEY MARKET SEGMENTS
1.4. RESEARCH METHODOLOGY

1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools & models

CHAPTER 2 EXECUTIVE SUMMARY

2.1. CXO PERSPECTIVE

CHAPTER 3 MARKET OVERVIEW

3.1. MARKET DEFINITION AND SCOPE
3.2. KEY FINDINGS

3.2.1. Top investment pockets
3.2.2. Top winning strategies

3.3. MARKET SHARE ANALYSIS, 2016
3.4. PORTER’S FIVE FORCES ANALYSIS

3.4.1. MARKET DYNAMICS
3.4.2. Drivers
3.4.3. Restraints
3.4.4. Opportunities

CHAPTER 4 NON-OPIOID PAIN PATCH MARKET, BY PATCH TYPE

4.1. OVERVIEW

4.1.1. Market size and forecast

4.2. CAPSAICIN PATCHES

4.2.1. Key market trends
4.2.2. Growth factors and opportunities
4.2.3. Market size and forecast

4.3. LIDOCAINE PATCHES

4.3.1. Key market trends
4.3.2. Growth factors and opportunities
4.3.3. Market size and forecast

4.4. DICLOFENAC PATCHES

4.4.1. Key market trends
4.4.2. Growth factors and opportunities
4.4.3. Market size and forecast

4.5. KETOPROFEN PATCHES

4.5.1. Key market trends
4.5.2. Growth factors and opportunities
4.5.3. Market size and forecast

4.6. METHYL SALICYLATE PATCHES

4.6.1. Key market trends
4.6.2. Growth factors and opportunities
4.6.3. Market size and forecast

4.7. OTHERS

4.7.1. Key market trends
4.7.2. Growth factors and opportunities
4.7.3. Market size and forecast

CHAPTER 5 NON-OPIOID PAIN PATCH MARKET, BY DISTRIBUTION CHANNEL

5.1. OVERVIEW

5.1.1. Market size and forecast

5.2. HOSPITAL PHARMACIES

5.2.1. Market size and forecast

5.3. ONLINE PHARMACIES

5.3.1. Market size and forecast

5.4. INDEPENDENT PHARMACIES & DRUG STORES

5.4.1. Market size and forecast

CHAPTER 6 NON-OPIOID PAIN PATCH MARKET, BY GEOGRAPHY

6.1. OVERVIEW
6.2. NORTH AMERICA

6.2.1. Key market trends
6.2.2. Key growth factors and opportunities
6.2.3. Market size and forecast

6.2.3.1. U.S. market size and forecast
6.2.3.2. Canada market size and forecast
6.2.3.3. Mexico market size and forecast

6.2.4. North America Non-opioid Pain Patch Market by Patch Type
6.2.5. North America Non-opioid Pain Patch Market by Distribution Channel 

6.3. EUROPE

6.3.1. Key market trends
6.3.2. Key growth factors and opportunities
6.3.3. Market size and forecast

6.3.3.1. Germany market size and forecast
6.3.3.2. France market size and forecast
6.3.3.3. UK market size and forecast
6.3.3.4. Italy market size and forecast
6.3.3.5. Spain market size and forecast
6.3.3.6. Rest of Europe market size and forecast

6.3.4. Europe Non-opioid Pain Patch Market by Patch Type
6.3.5. Europe Non-opioid Pain Patch Market by Distribution Channel

6.4. ASIA-PACIFIC

6.4.1. Key market trends
6.4.2. Key growth factors and opportunities
6.4.3. Market size and forecast

6.4.3.1. Japan market size and forecast
6.4.3.2. China market size and forecast
6.4.3.3. Australia market size and forecast
6.4.3.4. India market size and forecast
6.4.3.5. South Korea market size and forecast
6.4.3.6. Taiwan market size and forecast
6.4.3.7. Rest of Asia-Pacific market size and forecast

6.4.4. Asia-Pacific Non-opioid Pain Patch Market by Patch Type
6.4.5. Asia-Pacific Non-opioid Pain Patch Market by Distribution Channel

6.5. LAMEA

6.5.1. Key market trends
6.5.2. Key growth factors and opportunities
6.5.3. Market size and forecast

6.5.3.1. Brazil market size and forecast
6.5.3.2. Turkey market size and forecast
6.5.3.3. Saudi Arabia market size and forecast
6.5.3.4. South Africa market size and forecast
6.5.3.5. Rest of LAMEA market size and forecast

6.5.4. LAMEA Non-opioid Pain Patch Market by Patch Type
6.5.5. LAMEA Non-opioid Pain Patch Market by Distribution Channel 

CHAPTER 7 COMPANY PROFILES

7.1. TEIKOKU SEIYAKU CO., LTD.

7.1.1. Operating business segments
7.1.2. Business performance
7.1.3. Key strategic moves and developments

7.2. MYLAN N.V.

7.2.1. Operating business segments
7.2.2. Business performance
7.2.3. Key strategic moves and developments

7.3. GLAXOSMITHKLINE PLC

7.3.1. Operating business segments
7.3.2. Business performance
7.3.3. Key strategic moves and developments

7.4. TEH SENG PHARMACEUTICAL MFG. CO., LTD.

7.4.1. Operating business segments
7.4.2. Business performance
7.4.3. Key strategic moves and developments

7.5. ALLERGAN

7.5.1. Operating business segments
7.5.2. Business performance
7.5.3. Key strategic moves and developments

7.6. PFIZER, INC.

7.6.1. Operating business segments
7.6.2. Business performance
7.6.3. Key strategic moves and developments

7.7. HISAMITSU PHARMACEUTICAL CO. INC.

7.7.1. Operating business segments
7.7.2. Business performance
7.7.3. Key strategic moves and developments

7.8. ACORDA THERAPEUTICS

7.8.1. Operating business segments
7.8.2. Business performance
7.8.3. Key strategic moves and developments

7.9. IBSA INSTITUT BIOCHIMQUE SA, INC.

7.9.1. Operating business segments
7.9.2. Business performance
7.9.3. Key strategic moves and developments